A new infusion of $45 million will help Chimerix Inc. advance the development of clinical-stage antiviral candidates that target a number of viruses. CMX001 is in clinical trials for cytomegalovirus and adenovirus with potential for use as a smallpox countermeasure. Read More
Adventrx Pharmaceuticals Inc. is hoping to revive a sickle cell anemia drug that all but disappeared after a disappointing Phase III trial in 1999. Read More
A team from the University of Chicago has published unexpected insights into the origins of celiac disease, and the role of the vitamin A metabolite retinoic acid in its emergence. Read More
NEW YORK – Prostate cancer is a burgeoning disease market, but a recent spate of promising clinical news from the drug development industry is also offering optimism for the potential for an equally growing market for drug approvals to address the disease. Read More
Oxigene Inc., of South San Francisco, entered a cooperative research and development agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program to collaborate on a randomized Phase II study of Zybrestat (fosbretabulin) in combination with Avastin (bevacizumab, Genentech Inc./Roche AG) in patients with relapsed ovarian cancer. Read More
Idera Pharmaceuticals Inc., of Cambridge, Mass., said preclinical data showed that IMO-3100, an antagonist of Toll-like receptor 7 and TLR9, suppressed several key disease progression parameters in a model of lupus. The data, presented at the Dendritic Cells and Initiation of Adaptive Immunity Keystone Symposia, in Santa Fe, N.M., showed that IMO-3100 treatment led to a dose-dependent reduction in serum anti-DNA antibody levels, BUN levels and urine protein levels in NZBW/F1 mice. Read More
